Integra LifeSciences (IART) Stock Forecast & Price Target

$22.90 -0.03 (-0.13%)

(As of 10:15 AM ET)

Integra LifeSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 8 Analyst Ratings

Sell
3

Hold
4

Buy
1

Based on 8 Wall Street analysts who have issued ratings for Integra LifeSciences in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 3 have given a sell rating, 4 have given a hold rating, and 1 has given a buy rating for IART.

Consensus Price Target

$24.00
4.80% Upside

According to the 8 analysts' twelve-month price targets for Integra LifeSciences, the average price target is $24.00. The highest price target for IART is $35.00, while the lowest price target for IART is $18.00. The average price target represents a forecasted upside of 4.80% from the current price of $22.90.

Get the Latest News and Ratings for IART and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Integra LifeSciences and its competitors.

IART Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	4 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$24.00	$26.50	$28.88	$45.63
Forecasted Upside	4.80% Upside	38.09% Upside	37.04% Upside	16.57% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

IART Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IART Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Integra LifeSciences Stock vs. The Competition

Type	Integra LifeSciences	Medical Companies	S&P 500
Consensus Rating Score	1.75	2.80	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	4.67% Upside	26,931.56% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent IART News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sell ➝ Sell	$16.00 ➝ $22.00	-9.84%
10/14/2024	Truist Financial 2 of 5 stars		Lower Target	Hold ➝ Hold	$26.00 ➝ $21.00	+10.64%
10/7/2024	Bank of America 4 of 5 stars		Lower Target	Underperform ➝ Underperform	$26.00 ➝ $18.00	+4.23%
10/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Zimmerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral
7/30/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$40.00 ➝ $35.00	+37.09%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$24.00 ➝ $27.00	-9.12%
Get the Latest News and Ratings for IART and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.
5/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
5/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$45.00 ➝ $25.00	+8.04%
11/14/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+36.61%
7/12/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$58.00 ➝ $53.00	+28.33%
6/26/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$55.00 ➝ $44.00	+11.25%
6/8/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
5/24/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$56.00 ➝ $43.00	+6.23%
5/23/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:35 AM ET.

IART Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Integra LifeSciences is $24.00, with a high forecast of $35.00 and a low forecast of $18.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" IART shares.
: According to analysts, Integra LifeSciences's stock has a predicted upside of 4.80% based on their 12-month stock forecasts.
: Over the previous 90 days, Integra LifeSciences's stock had 1 upgrade by analysts.
: Integra LifeSciences has been rated by research analysts at Bank of America, BTIG Research, Citigroup, and Truist Financial in the past 90 days.
: Analysts like Integra LifeSciences less than other "medical" companies. The consensus rating for Integra LifeSciences is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IART compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

This page (NASDAQ:IART) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integra LifeSciences (IART) Stock Forecast & Price Target